3,957
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Pfizer's recently active trials. Comparator arms are excluded.
- PF-07220060 + PF-07104091 combination dose escalation8 trials
- Rimegepant5 trials
- Berobenatide4 trials
- Elranatamab4 trials
- PG44 trials
- 20-valent pneumococcal conjugate vaccine (20vPnC)4 trials
Upcoming readouts
Next primary completion dates among Pfizer's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Dec 2026A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resista…Phase 3
- May 2027A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moder…Phase 3
- Sept 2027A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely …Phase 3
- Dec 2027Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccin…Phase 3
- Jan 2028A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has …Phase 2
- Feb 2028A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised AdultsPhase 3
Top therapeutic areas
Conditions studied most often across Pfizer's recently active trials.
- Obesity8 trials
- Atopic Dermatitis6 trials
- Alopecia Areata5 trials
- Pneumococcal Disease5 trials
- Overweight5 trials
- Breast Cancer5 trials
Pfizer pipeline by phase
The main study drugs across 195 active trials Pfizer leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 345 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| PF-08634404 | 11 | 10 | Oct 2027 est. | NCT07578649 · NCT07222800 · NCT07222566 |
| vepdegestrantARV-471 | 8 | 1 | Dec 2026 est. | NCT05909397 · NCT05654623 · NCT07231991 |
| MET097PF-08653944 | 6 | 2 | Jan 2027 est. | NCT07595549 · NCT07400653 · NCT07311850 |
| Disitamab vedotin | 5 | 1 | Dec 2026 est. | NCT05911295 · NCT06157892 · NCT06003231 |
| RSVpreF | 5 | 3 | Jan 2027 est. | NCT07819097 · NCT07653100 · NCT07543380 |
| Etrasimod | 4 | 3 | Jun 2029 est. | NCT03950232 · NCT07470879 · NCT05287126 |
| PG4 | 4 | 3 | May 2027 est. | NCT07660198 · NCT07629440 · NCT07573462 |
| Ritlecitinib | 4 | — | Dec 2026 est. | NCT06163326 · NCT06072183 · NCT07228390 |
| Berobenatide | 3 | — | Mar 2028 est. | NCT07794774 · NCT07794761 · NCT07792954 |
| Encorafenib | 3 | — | Oct 2026 est. | NCT04657991 · NCT04607421 · NCT05217446 |
| marstacimabPF-06741086 | 3 | 3 | May 2027 est. | NCT05611801 · NCT05145127 · NCT06703606 |
| MevrometostatPF-06821497 | 3 | 2 | Dec 2026 est. | NCT07028853 · NCT06629779 · NCT06551324 |
| Sigvotatug Vedotin | 3 | 2 | Jun 2027 est. | NCT06758401 · NCT06012435 · NCT04389632 |
| Tilrekimig | 3 | 1 | Mar 2028 est. | NCT07783425 · NCT07772921 · NCT07765888 |
| 20vPnC | 2 | 1 | May 2027 est. | NCT07754539 · NCT07023081 |
| Abrocitinib | 2 | 2 | May 2027 est. | NCT06807281 · NCT06807268 |
| ibuzatrelvir | 2 | 2 | Sept 2027 est. | NCT07013474 · NCT06679140 |
| PF-07220060 | 2 | — | Sept 2026 est. | NCT06760637 · NCT04557449 |
| PF-07248144 | 2 | 2 | Jul 2027 est. | NCT07062965 · NCT04606446 |
| PF-08046054 | 2 | 2 | Jan 2028 est. | NCT07144280 · NCT05208762 |
| Ritlecitinib 100 mg | 2 | 2 | Mar 2028 est. | NCT07733765 · NCT06873945 |
| Ritlecitinib higher dose | 2 | 1 | Dec 2026 est. | NCT07029828 · NCT07029711 |
| VLA15 | 2 | 1 | Dec 2026 est. | NCT07500506 · NCT07226882 |
| Avelumab | 1 | — | Dec 2026 est. | NCT05059522 |
| Brentuximab vedotin | 1 | — | — | NCT04404283 |
| C.difficile vaccine | 1 | 1 | Dec 2028 est. | NCT07282665 |
| Dazukibart | 1 | 1 | Jul 2031 est. | NCT06698796 |
| Enzalutamide | 1 | — | — | NCT02319837 |
| Multivalent Group B streptococcus vaccine | 1 | 1 | Nov 2028 est. | NCT07160244 |
| nirmatrelvir | 1 | 1 | — | NCT05261139 |
| PF-06801591 | 1 | — | — | NCT04165317 |
| PF-06823859 | 1 | 1 | Jul 2030 est. | NCT05895786 |
| PF-06838435/ fidanacogene elaparvovec | 1 | — | — | NCT03861273 |
| PF-06939926 | 1 | — | — | NCT04281485 |
| PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy | 1 | — | — | NCT04370054 |
| PG4 Multivalent Vaccine | 1 | — | Jun 2027 est. | NCT07794748 |
| Rimegepant (PF-07899801) | 1 | 1 | Jul 2030 est. | NCT04743141 |
| Rimegepant/BHV3000 | 1 | 1 | Jan 2029 est. | NCT04649242 |
| RSVpreF Vaccine | 1 | 1 | Feb 2028 est. | NCT07768345 |
| talazoparib plus enzalutamide | 1 | — | — | NCT04821622 |
| Talazoparib with enzalutamide | 1 | — | — | NCT03395197 |
| taldefgrobep alfa | 1 | — | — | NCT05337553 |
| Testing of hepatic AAV Vector integration | 1 | 1 | Feb 2040 est. | NCT05568719 |
| tofacitinib | 1 | — | Mar 2027 est. | NCT04624230 |
| troriluzole | 1 | — | — | NCT03701399 |
Phase 217 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Palbociclib | 3 | — | Dec 2026 est. | NCT05226871 · NCT03709680 · NCT06495164 |
| PF-07275315 | 3 | 3 | Oct 2026 est. | NCT07363694 · NCT06977581 · NCT05995964 |
| Osivelotor | 2 | 1 | Feb 2027 est. | NCT05431088 · NCT06507904 |
| PF-08049820 | 2 | 2 | Feb 2028 est. | NCT07216027 · NCT07597928 |
| PF-08653945 | 2 | 1 | Jan 2027 est. | NCT07575932 · NCT07725809 |
| ponsegromab | 2 | 1 | Jan 2028 est. | NCT06989437 · NCT07663630 |
| ATM-AVI | 1 | 1 | Mar 2027 est. | NCT05639647 |
| Elranatamab (PF-06863135) | 1 | — | — | NCT04649359 |
| Inotuzumab ozogamicin | 1 | 1 | May 2033 est. | NCT05748171 |
| Low Dose PF-07328948 | 1 | 1 | Nov 2027 est. | NCT06991257 |
| Part A: ATM-AVI Single Dose, Cohorts 1-4 | 1 | 1 | Apr 2027 est. | NCT06462235 |
| PF-06835375 | 1 | 1 | Aug 2028 est. | NCT05070845 |
| PF-07104091 monotherapy dose escalation | 1 | — | Dec 2026 est. | NCT04553133 |
| PF-07220060 CDK4 inhibitor | 1 | — | — | NCT06105632 |
| PF-07868489 | 1 | — | Aug 2028 est. | NCT07073820 |
| Ritlecitinib 50 mg | 1 | 1 | Dec 2026 est. | NCT07219615 |
| Vaccine Candidate #1 | 1 | 1 | Jun 2027 est. | NCT07431853 |
Phase 130 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| PF-07328948 | 2 | 2 | Feb 2027 est. | NCT07315360 · NCT07269301 |
| Atirmociclib | 1 | 1 | Aug 2027 est. | NCT07677358 |
| C. difficile vaccine formulation 1. | 1 | — | Jun 2031 est. | NCT05805826 |
| E coli vaccine 1 Dose A | 1 | 1 | May 2028 est. | NCT07122986 |
| Mervometostat (PF-06821497) | 1 | 1 | Apr 2028 est. | NCT03460977 |
| MET233 and MET097 | 1 | 1 | — | NCT06924320 |
| Oral [14C] PF-07799544 | 1 | — | — | NCT07578636 |
| PF-07220060 + PF-07104091 combination dose escalation | 1 | — | Feb 2027 est. | NCT05262400 |
| PF-07799544 | 1 | — | Aug 2027 est. | NCT05538130 |
| PF-07799933 | 1 | — | Aug 2027 est. | NCT05355701 |
| PF-07832837 | 1 | 1 | Jun 2027 est. | NCT06564389 |
| PF-07934040 | 1 | — | Oct 2026 est. | NCT06447662 |
| PF-07985631 | 1 | 1 | Dec 2027 est. | NCT06994897 |
| PF-07994525 | 1 | 1 | Jul 2029 est. | NCT07426757 |
| PF-07999415 | 1 | — | — | NCT06965465 |
| PF-08032562 | 1 | 1 | Apr 2029 est. | NCT07318805 |
| PF-08046033 | 1 | 1 | Jul 2028 est. | NCT07519655 |
| PF-08046050 | 1 | 1 | Sept 2029 est. | NCT06131840 |
| PF-08046876 | 1 | 1 | Jul 2028 est. | NCT07090499 |
| PF-08052667 | 1 | 1 | Jan 2030 est. | NCT07206225 |
| PF-08065010 | 1 | 1 | Sept 2027 est. | NCT07235163 |
| PF-08103402 | 1 | 1 | Mar 2027 est. | NCT07660731 |
| PF-08154225 | 1 | — | Feb 2031 est. | NCT07782450 |
| PF-08642534 | 1 | — | Apr 2027 est. | NCT07731139 |
| PG4 vaccine in Buffer 1 with low dose PA-001 | 1 | — | Oct 2027 est. | NCT07086677 |
| Prifetrastat | 1 | — | — | NCT07731100 |
| prifetrastat Reference | 1 | 1 | Dec 2026 est. | NCT07721402 |
| SEA-CD70 | 1 | — | Jul 2027 est. | NCT04227847 |
| tilrekimig and rHuPH20 | 1 | 1 | Feb 2027 est. | NCT07792941 |
| Zavegepant | 1 | 1 | Aug 2027 est. | NCT06995729 |
Phase 49 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Tucatinib | 8 | 1 | Dec 2026 est. | NCT07768358 · NCT05253651 · NCT05132582 |
| Elranatamab | 7 | 4 | Aug 2027 est. | NCT06057402 · NCT06152575 · NCT05623020 |
| Rimegepant | 5 | 3 | Nov 2026 est. | NCT07609914 · NCT07729462 · NCT06641466 |
| Lorlatinib | 3 | 1 | Dec 2026 est. | NCT05144997 · NCT03052608 · NCT06487078 |
| Tisotumab Vedotin | 2 | 1 | Dec 2028 est. | NCT06952660 · NCT03485209 |
| Binimetinib only treatment | 1 | 1 | Jul 2029 est. | NCT05203172 |
| Cardiac Imaging | 1 | — | Apr 2029 est. | NCT05295290 |
| crizotinib | 1 | — | Mar 2028 est. | NCT05160922 |
| Rimegepant 75 mg ODT | 1 | 1 | Jan 2028 est. | NCT07685769 |
Derived from 195 active trials Pfizer leads; 194 name an intervention, folding into 101 phased drugs. 3 interventions carry no registry phase (observational studies, tests and devices) and are not shown. 1 trial names a placebo or non-interventional arm and is excluded. This is ComplyRx's reading of the registry, not Pfizer's own pipeline disclosure.
Pfizer trials
The 50 most significant of Pfizer's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting PneumoniaNCT07251465Receipt of PCV20 | — | Not yet scored | OngoingActive, not recruiting | 846,279 est. | 30 Sept 2026 |
| A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyNCT07494656tafamidis 61mg (based on prescription data) | — | Locked · track to reveal | OngoingActive, not recruiting | 1 est. | 30 Sept 2026 |
| A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaNCT04657991Encorafenib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 257 est. | 30 Oct 2026 |
| A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779PF-06821497 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 900 est. | 2 Dec 2026 |
| B7981027A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataNCT07029711Ritlecitinib higher dose | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 208 est. | 2 Dec 2026 |
| A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.NCT07228390Ritlecitinib | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 128 est. | 8 Dec 2026 |
| Lorlatinib Continuation StudyNCT05144997Lorlatinib | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 76 est. | 28 Dec 2026 |
| A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or ObesityNCT07725809PF-08653945 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 57 est. | 13 Jan 2027 |
| A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20NCT07792941tilrekimig and rHuPH20 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 12 est. | 11 Feb 2027 |
| A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy AdultsNCT06507904Osivelotor | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 52 est. | 19 Feb 2027 |
| A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid TumorsNCT05262400PF-07220060 + PF-07104091 combination dose escalation | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 235 est. | 26 Feb 2027 |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)NCT05548127ARV-471 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 37 est. | 24 Mar 2027 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate AsthmaNCT07660731PF-08103402 | Phase 1 | Not yet scored | OngoingRecruiting | 133 est. | 30 Mar 2027 |
| Tranquillo LTEA 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoNCT06163326Ritlecitinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 394 est. | 31 Mar 2027 |
| Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims DataNCT07821216ritlecitinib | — | Not yet scored | OngoingNot yet recruiting | 7,500 est. | 20 Apr 2027 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsNCT06524414PG4 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 605 est. | 1 May 2027 |
| A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe EczemaNCT06807268Abrocitinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 150 est. | 2 May 2027 |
| EFFECT-UCA Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative ColitisNCT06294925Etrasimod | — | Not yet scored | OngoingActive, not recruiting | 360 est. | 13 May 2027 |
| A Study to Learn About the Safety and Immune Responses of RSVpreF in Older AdultsNCT07819097RSVpreF | Phase 3 | Not yet scored | OngoingNot yet recruiting | 600 est. | 15 May 2027 |
| A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to AdultsNCT07794748PG4 Multivalent Vaccine | Phase 3 | Not yet scored | OngoingNot yet recruiting | 4,670 est. | 7 Jun 2027 |
| A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesNCT04227847SEA-CD70 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 170 est. | 4 Jul 2027 |
| SOLIS-1A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932PF-08653945 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 940 est. | 4 Aug 2027 |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701PF-07799933 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 103 est. | 31 Aug 2027 |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130PF-07799544 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 148 est. | 31 Aug 2027 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy AdultsNCT07235163PF-08065010 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 100 est. | 1 Sept 2027 |
| VESPER-4Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityNCT07311850MET097 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 3,578 est. | 21 Sept 2027 |
| A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedNCT07013474ibuzatrelvir | Phase 3 | Locked · track to reveal | OngoingRecruiting | 300 est. | 27 Sept 2027 |
| A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653PF-08653944 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,078 est. | 12 Oct 2027 |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerNCT06966453Disitamab vedotin | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 74 est. | 25 Oct 2027 |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)NCT06215118Elranatamab | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 100 est. | 16 Nov 2027 |
| Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and AdolescentsNCT07660198PG4 | Phase 3 | Not yet scored | OngoingRecruiting | 1,200 est. | 2 Dec 2027 |
| A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in IndiaNCT07685769Rimegepant 75 mg ODT | Phase 4 | Not yet scored | OngoingRecruiting | 60 est. | 4 Jan 2028 |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatigueNCT06989437ponsegromab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 982 est. | 17 Jan 2028 |
| A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised AdultsNCT07768345RSVpreF Vaccine | Phase 3 | Locked · track to reveal | OngoingRecruiting | 440 est. | 2 Feb 2028 |
| A Study to Learn About Study Medicine Called PF-08049820 in People With EczemaNCT07216027PF-08049820 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 165 est. | 2 Feb 2028 |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280PF-08046054 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 680 est. | 10 Mar 2028 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaNCT07765888Tilrekimig | Phase 3 | Locked · track to reveal | OngoingRecruiting | 375 est. | 10 Mar 2028 |
| A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or ObesityNCT07792954Berobenatide | Phase 3 | Not yet scored | OngoingNot yet recruiting | 300 est. | 14 Mar 2028 |
| ALLEGRO-100A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataNCT06873945Ritlecitinib 100 mg | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,330 est. | 19 Mar 2028 |
| PRESTOCharacterization And Clinical Outcomes of AA Patients Treated With RitlecitinibNCT06531109Ritlecitinib | — | Not yet scored | OngoingActive, not recruiting | 450 est. | 15 Apr 2028 |
| Study of Pregnancy Outcomes in Women Exposed to Rimegepant During PregnancyNCT05198245Rimegepant | — | Not yet scored | OngoingActive, not recruiting | 1 est. | 17 Apr 2028 |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977Mervometostat (PF-06821497) | Phase 1 | Locked · track to reveal | OngoingRecruiting | 453 est. | 20 Apr 2028 |
| A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataNCT07733765Ritlecitinib 100 mg | Phase 3 | Not yet scored | OngoingRecruiting | 336 est. | 26 Apr 2028 |
| ATTR-CM: A Multi-country, Non-interventional Disease RegistryNCT06651073Observational | — | Not yet scored | OngoingActive, not recruiting | 350 est. | 28 Apr 2028 |
| A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or ObesityNCT07595549PF-08653944 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 954 est. | 4 May 2028 |
| A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight LossNCT07663630ponsegromab | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 80 est. | 5 May 2028 |
| A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With MigraineNCT07609914Rimegepant | Phase 4 | Locked · track to reveal | OngoingRecruiting | 400 est. | 15 May 2028 |
| A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)NCT07823608Berobenatide | Phase 3 | Not yet scored | OngoingNot yet recruiting | 258 est. | 19 Jun 2028 |
| A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499PF-08046876 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 540 est. | 8 Jul 2028 |
| Phase 1 Study of PF-08046033 in Advanced Solid TumorsNCT07519655PF-08046033 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 250 est. | 14 Jul 2028 |